Isotopes & Radiation

The Department of Energy’s National Nuclear Security Administration and Office of Environmental Management (EM) have signed the first contracts under the DOE’s Uranium Lease and Take-back Program with SHINE Technologies. The DOE called it a milestone in its effort to increase domestic production of molybdenum-99 (Mo-99), a medical isotope used in more than 40,000 medical procedures in the United States each day, without the use of high-enriched uranium.

SHINE Technologies, of Janesville, Wis., is one of the NNSA’s cooperative agreement partners. In October 2021, the NNSA awarded SHINE $35 million to support its efforts to produce Mo-99 commercially by the end of 2023.

Click here for more information on the NNSA efforts to establish a reliable supply of Mo‑99 without the use of HEU.

Secretary of energy Jennifer Granholm and secretary of health and human services (HHS) Xavier Becerra on December 20 jointly certified that the worldwide supply of the medical radioisotope molybdenum-99 produced without the use of high-enriched uranium is now sufficient to meet the needs of patients in the United States.

The Department of Energy’s National Nuclear Security Administration has issued a cooperative agreement worth $13 million to Niowave, of Lansing, Mich., to support the commercial production of molybdenum-99, a critical isotope used in more than 40,000 medical procedures in the United States each day, including the diagnosis of heart disease and cancer.

AccApp'21, the 14th International Topical Meeting on Nuclear Applications of Accelerators, runs through December 4 and is being held as an embedded topical at the 2021 ANS Winter Meeting and Technology Expo in Washington, D.C. The meeting was to be held April 5-9, 2020, at the International Atomic Energy Agency’s headquarters in Vienna, Austria—and it was to be known as AccApp’20—but it was postponed because of COVID-19.

AccApp'21 is organized by ANS’s Accelerator Applications Division and cosponsored by Texas A&M University, the Department of Energy’s National Nuclear Security Administration, and the IAEA. The meeting’s focus is on the following areas:

• The production and use of accelerator-produced neutrons, photons, electrons, and other particles for scientific and industrial purposes.
• The production or destruction of radionuclides significant for energy, medicine, cultural heritage, or other endeavors.
• Safety and security applications.
• Medical imaging, diagnostics, and therapeutic treatment.

The Canadian Nuclear Safety Commission (CNSC) has amended Ontario Power Generation’s (OPG) operating license for its Darlington nuclear power station near Clarington, Ontario, allowing the company to produce the medical radioisotope molybdenum-99 using Darlington’s Unit 2 CANDU reactor. OPG subsidiary Laurentis Energy Partners, in conjunction with BWXT Medical, is leading the program to produce Mo-99 at Darlington.

What is one thing that bridges, oil wells, and cancer treatment therapies have in common? Reliance on radioisotopes. Radioisotopes have played an important role in our society for decades, yet their benefits often go unrecognized. As Congress makes progress on new bipartisan infrastructure legislation, radioisotopes are essential to bringing new infrastructure projects to life.

The Department of Energy’s National Nuclear Security Administration has issued a cooperative agreement worth $35 million to SHINE Technologies, based in Janesville, Wis., to support the commercial production of molybdenum-99, a critical isotope used in more than 40,000 medical procedures in the United States each day, including the diagnosis of heart disease and cancer.

ARTMS, a Canadian producer of medical isotopes, announced that it has registered the cyclotron production of gallium-68 with the government of Canada, filing a Type 1 Master File with the Health Products & Food Branch of Health Canada. The Ga-68 radioisotope is used in nuclear medicine diagnostic procedures utilizing positron emission tomography (PET) imaging.

An Oak Ridge National Laboratory researcher has built a device that can speed up the separation of the medical radioisotope actinium-225 from irradiated thorium targets and withstand the high-radiation environment of a hot cell. In July, ORNL announced that Kevin Gaddis, a chemistry technician at the lab, had built and tested a prototype and was working to secure a patent for a device that cut separations time by 75 percent.

A team of researchers from the University of Georgia have shown that radioactive contamination in the Fukushima Exclusion Zone can be measured through its resident snakes.

One of the biggest challenges in training for incidents and emergencies that involve high-radiation-dose hazards is balancing between realism and safety. To be truly prepared for the realities of real-world nuclear and radiological emergencies, responder personnel need experience against those hazards but without introducing additional and very personal risks associated with unnecessary radiation exposure. The difficulty is in figuring out how we can achieve a level of realism that encompasses the entire process, from the initial detection of a hazard or threat, through its characterization, to recommending actions and leadership decision-making.

Physicists from the Massachusetts Institute of Technology and other institutions have measured the effect of a single neutron in a molecule of radium monofluoride and hypothesize that radioactive molecules could be used as a tool to explore why there is more matter than antimatter in the universe. The research team’s findings were published in the journal Physical Review Letters on July 7, and on the same day, an article published online by MIT News explained the implications of their work.

“The American Nuclear Society is monitoring the situation at the Taishan reactor site in China. According to Framatome and the plant operator CGN, the plant is operating within established safety parameters.

Hargraves

Atomic fission can provide all the world’s people with as much emission-free electricity as they need for prosperity, but the cost of nuclear energy has risen due to excessive regulations that have been enacted in reaction to the general public's excessive fear of radiation. That’s according to Robert Hargraves, who teaches energy policy at Dartmouth’s Osher Lifelong Learning Institute and is a cofounder of nuclear engineering company ThorCon International.

In an article published by RealClearEnergy, Radiation: More Terrifying Than Night Air?, Hargraves posits that many people fear radiation because they don’t understand it, much like Americans who believed until the 20th century that night air was poisonous.

Kandasamy

Jhansi R. Kandasamy, vice president of engineering at GE Hitachi Nuclear Energy (GEH), will be the featured guest at the next edition of the ANS Young Members Group’s Rad Talks series.

Register now for the event on Tuesday, May 18, 6:30–8 p.m. EDT. Please note that participation is limited to allow for an interactive discussion.

Details: Kandasamy joined GEH in September 2015 as vice president of engineering, having overall responsibility for operating nuclear plant technical support, modifications, and design, and for small modular reactor design and development. Over the past 30 years, she has held positions in virtually all disciplines of the nuclear power industry. She has worked at the Limerick, Palo Verde, Oyster Creek, Salem, and Hope Creek nuclear power plants. Prior to joining GEH, she worked for Bechtel, Philadelphia Electric Company, Exelon, and PSEG.

Dickman

Paul Dickman, former senior official with the Nuclear Regulatory Commission who served as the study director for the ANS Special Committee on the Fukushima Daiichi accident, discussed Japan’s plans to dispose of Fukushima wastewater during an appearance on CNBC’s Street Signs Asia with hosts Amanda Drury and Tanvir Gill on April 16.

Appearing on the show as an ANS spokesman, Dickman assured the hosts that there will be no negative environmental impact from releasing the advanced liquid waste processing system (ALPS)-treated water into the Pacific Ocean. “The Japanese government has done an extraordinary effort to mitigate any harm that would be from the release of this water,” Dickman said. “Frankly, they’ve diluted it to such an extent that it would hardly be detectable above background (radiation).”

The Japanese government will soon announce the decision to dispose of stockpiled Fukushima wastewater into the Pacific Ocean, according to an AP News story published last Friday. The decision is years in the making and follows the guidelines from a panel of government-appointed experts named the Subcommittee on Handling of the ALPS-Treated Water (ALPS Subcommittee).

Screenshot of the video from Vice.

Vice News has published a video on YouTube that follows two farmers from the Fukushima Prefecture, Noboru Saito and Koji Furuyama. Saito, who grows many different crops on his farm, says that the rice grown in the area is consistently rated as the best. Furuyama specializes in peaches and explains his strategy to deal with the stigma of selling fruit from Fukushima: grow the best peaches in the world.

A film titled The Toxic Pigs of Fukushima gets top billing as part of The Short List with Suroosh Alvi, an online documentary series curated by the founder of the media company Vice. The film, which first aired on Vice TV on January 31, follows local hunters who have been enlisted to dispose of radiated wild boars that now roam abandoned streets and buildings in Fukushima Prefecture, Japan, in the aftermath of the 2011 earthquake and tsunami that caused the nuclear accident there.

Wisconsin-based SHINE Medical Technologies announced on November 4 that its Therapeutics division has made its first commercial sales of lutetium-177 to multiple customers. Lu-177 is a therapeutic isotope in demand by clinical trial sponsors because of its potential to treat a range of cancers.

SHINE said that its production process enables the company to produce the high specific activity, non-carrier-added Lu-177 that is required by today’s clinical trials. In the short term, SHINE will produce Lu-177 at Building One of the company’s Janesville campus while a larger facility is being constructed exclusively for the production of the radioisotope. Building One, which was completed in 2018, houses SHINE’s first integrated, full-size production system and is used to train staff and develop operating history with the equipment.

Groundbreaking for the larger facility is expected in November. According to SHINE, the new production facility will be able to scale to support the company’s anticipated Lu-177 demand for the next five years. It will be capable of producing more than 300,000 doses of Lu-177 per year, the company said.